Ad Header



The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Mylan to pay $465 million over EpiPen Medicaid rebate dispute

Mylan NV will pay $465 million to settle questions of whether it underpaid U.S. government healthcare programs by misclassifying its EpiPen emergency allergy treatment.

Read More »

Pfizer abandons plan to split into two companies

Pfizer, which was considering a split into two companies for more than two years, said it would not do so because the move would not create any shareholder value.

Read More »

Endo CEO steps down; successor named

Endo International Plc said Chief Executive Rajiv De Silva had stepped down and would be replaced by generics division head Paul Campanelli.

Read More »

Novo Nordisk cuts forecasts on tough U.S. market

Novo Nordisk cut its forecast for full-year 2016 profit growth and said it expected tough competition in the United States to pressure prices in 2017.

Read More »

Bristol-Myers shares hit by decline of Yervoy

Bristol-Myers Squibb reported disappointing 2Q 2016 sales of its Yervoy melanoma treatment.

Read More »

Sales of Revlimid drive Celgene profit

Celgene Corp. exceeded expectations for second-quarter 2016 earnings on the strength of its flagship multiple myeloma drug Revlimid and growth in newer medicines.

Read More »

Lilly sales beat estimates, helped by newer drugs

Eli Lilly reported better-than-expected second-quarter 2016 sales and predicted average annual revenue growth of at least 5 percent through the end of the decade.

Read More »

Biogen profit easily beats Street view; CEO to leave

Biogen reported Q2 profit that blew past Wall Street estimates; Chief Executive George Scangos will step down in the coming months once a successor is found.

Read More »

Roche beats forecasts on new drugs, one-off gain

Roche beat market expectations for adjusted net income in the first-half 2016, helped by cancer drug sales but also inflated by a one-off gain from its pensions scheme.

Read More »

Abbott quarterly sales and profit exceed forecast

Abbott Laboratories reported better-than-expected quarterly sales and profit with strong sales in its medical device business.

Read More »

Ad Right Top


Extensive pharmaceutical business and marketing intelligence. For back issues, please contact

June 2019 Focus: Payer access, biotech/biopharma, DTC, rare diseases, and more!


Ad Right Bottom